
MNLO
Healthcare · Biotechnology · $82.5M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2020
EPS trend, 90 days to now · +10.5% over 90 days · 30-day revisions 4 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2020 | Time not confirmed | -0.17 | -0.15 | +11.8% |
| Aug 6, 2020 | Time not confirmed | -0.25 | -0.14 | +44.0% |
| May 11, 2020 | Time not confirmed | -0.54 | -0.95 | -75.9% |
| Mar 3, 2020 | Time not confirmed | -0.83 | -0.89 | -7.2% |
| Oct 31, 2019 | Time not confirmed | -0.77 | -0.70 | +9.1% |
| Aug 1, 2019 | Time not confirmed | -0.84 | -0.69 | +17.9% |
| May 2, 2019 | Time not confirmed | -0.81 | -0.81 | 0.0% |
| Feb 27, 2019 | Time not confirmed | -0.81 | -0.76 | +6.2% |
| Nov 7, 2018 | Time not confirmed | -0.89 | -0.56 | +37.1% |
| Aug 1, 2018 | Time not confirmed | -0.79 | -0.36 | +54.4% |
| May 9, 2018 | Time not confirmed | -0.66 | -0.72 | -9.1% |
| Jan 26, 2018 | Time not confirmed | -0.69 | -1.80 | -160.9% |
Menlo Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of…